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Introduction
The Second Symposium on the Molecular Biology of Breast
Cancer comes 5 years after the first Lillehammer meeting in
1995. The chairperson of the organizing committee, Anne-
Lise Børresen-Dale (Norwegian Radium Hospital, Oslo,
Norway), reminded the 250 participants of the momentous
changes that have occurred in the field in the intervening
years, not least the death of the co-organizer of the first
meeting, Ruth Sager, who sadly died of bladder cancer in
1997. This second symposium was held in her memory.
A major goal of the organizers was to foster ties between
basic and clinical scientists, and to promote translational
collaborations. In his opening address Stener Kvinnsland
(The Norwegian Cancer Society, Oslo, Norway) described
the trends in breast cancer incidence and mortality.
Despite improvements in survival, breast cancer remains a
major cause of death, with approximately 385000 deaths
per year (in 1997). Kvinnsland pointed out that a stage
migration rather than a decrease in incidence rate is likely
over the next decade. Only when future molecular break-
throughs are incorporated into the clinic can we expect a
reduction in incidence rates. Introductory lectures from the
perspectives of a patient (Susan Leigh, National Coalition
for Cancer Survivorship, Tucson, AZ, USA), a clinician
(Nancy Davidson, John Hopkins Oncology Center, Balti-
more, MA, USA) and a scientist (Carlo Croce, Kimmel
Cancer Center, Philadelphia, PA, USA) opened the
meeting (and the delegates minds) very well.
Inherited breast cancer
Barbara L Weber (University of Pennsylvania, Philadelphia,
PA, USA) started the session with the question regarding
whether genetic testing for BRCA1 and BRCA2 is ready for
implementation. She reminded the participants that only
5–10% of all early onset (age below 40 years) breast cancer
patients have mutations in BRCA1 or BRCA2. Weber pre-
sented data demonstrating how breast cancer penetrance in
BRCA1 mutation carriers varies with the population studied
– from 87% by age 85 years in high-risk families to 50% by
age 69 years or even lower in population-based samples.
Both Weber and Bruce Ponder (Cambridge University,
Cambridge, UK) emphasized that penetrance may vary with
the site of the mutation, and that families with mutations in
the middle region of BRCA2 may have at least reduced
breast cancer penetrance, if not higher ovarian cancer inci-
dence. Ponder reminded us that knowledge of the mutation
status of the family may also be of significance for male
family members. The risk of prostate and colon cancer are
threefold and fourfold elevated in BRCA1 mutation carriers,
whereas the risk of prostate and pancreas cancer is ele-
vated threefold in BRCA2 mutation carriers. The data pre-
sented here provide a strong rationale for expanding
BRCA1 and  BRCA2 testing at institutions where the coun-
selling expertise is available. A number of prevention trials
are in progress, which hopefully will soon yield useful infor-
mation to individuals with identified mutations. Mike Stratton
(Institute of Cancer Research, Surrey, UK) described the
pathology of inherited breast tumours. He presented data
suggesting that, although BRCA1/BRCA2 tumours cannot
be diagnosed microscopically, they tend to be of higher
grade than sporadic tumours. There was also a slight
increase in medullary tumours in BRCA1 mutation carriers.
Immunohistochemically, BRCA1 (but not BRCA2) tumours
are less likely to be oestrogen receptor (ER)-, progesterone
receptor- and p53-positive than are sporadic tumours. Both
BRCA1 and BRCA2 tumours have a lower degree of c-
erbB2-positive tumours, whereas cyclin D is more likely to
be upregulated in BRCA1 than in BRCA2 tumours.Breast Cancer Research    Vol 2 No 3 Jones and Ursin
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Åke Borg (Lund University, Lund, Sweden) further
described data from comparative genomic hybridization
(CGH) studies suggesting that there are distinct differ-
ences between BRCA1, BRCA2 and other familial
cancers. Preliminary results from cDNA microarray analy-
ses suggest that BRCA1 and BRCA2 have distinct gene
expression profiles, which include genes that are involved
in cell cycle control. Both Borg and Stratton suggested
that there may be additional undiscovered major breast
cancer susceptibility genes. There are a number of non-
BRCA1/BRCA2 familial cases of ductal cancers with
lower grade of mitosis that are ER-positive and proges-
terone-receptor-positive, as well as cases of invasive
lobular cancer, and CGH analyses suggest that these
tumours have distinct patterns of chromosomal alterations.
Manfred Schwab (German Cancer Center, Heidelberg,
Germany) ended the session with intriguing late-breaking
news suggesting that there may be a BRCA2-modifying
gene or a fragile site on 9p23-24. Data from three
unlinked families with male breast cancer suggest that this
is a region of frequent aberrations.
Hormonal influence on breast cancer: what is
new?
The role of coactivators in the action of oestrogen was
summarized by Myles Brown (Dana Farber Institute,
Boston, MA, USA). He reminded the participants that the
effect of endocrine therapy is limited and specific
responses may be determined by the ER coregulators that
are expressed. Important coactivators include p300/
CREB binding protein, and the steroid receptor coactiva-
tor-1 family. Results presented further suggest that growth
factors can help modulate oestrogen activity through acti-
vation of mitogen-activated protein kinase. AIB1, a
member of the steroid receptor coactivator-1 family that is
amplified in ER-positive breast cancers, can be activated
by mitogen-activated protein kinase, which further causes
the activation of p300 and histone acetyltransferase activity.
Kathryn Horwitz (University of Colorado, Denver, CO, USA)
gave an excellent talk on the role of progesterone. Recent
evidence suggests that postmenopausal hormone replace-
ment therapy with oestrogen and a synthetic version of
progesterone increases the risk of breast cancer. The rate
and dose of progesterone administration is important, and
determines whether there will be growth stimulation or inhi-
bition. Continuous progesterone treatment appears to
inhibit growth. Data was also presented on the two proges-
terone receptors A and B in different types of tissue. Prog-
esterone receptors A and B are coexpressed, but the ratio
varies from tissue to tissue. In humans there is an excess of
type B receptors, and in human breast cancer there is a
large variation in the ratio of type A to type B receptors.
This could influence the responses of the tumour to prog-
esterone, because a number of genes appear to be differ-
entially regulated by type A and type B receptors. Oestro-
gen upregulates both type A and type B receptors. Horwitz
suggested that these different types of receptors may
provide the basis for selective progesterone receptor mod-
ulators, new progesterone ligands that target only one
progesterone receptor or one tissue. The distribution of
type A versus that of type B receptors may also be impor-
tant as a prognostic marker in breast cancer.
Suzanne Fuqua (Baylor College, Houston, TX, USA)
described expression array experiments using RNA from
tamoxifen-sensitive and tamoxifen-resistant MCF-7 tumours
isolated from athymic mouse xenograft models. The data
suggest specific tamoxifen-resistant RNA profiles, with an
endothelial receptor-related protein overexpressed in these
tumours. These intriguing results are in accord with what is
known about the role of angiogenesis/intratumoural
microvessel density in breast cancer prognosis. Jan Åke
Gustafsson (Karolinska Institute, Huddinge, Sweden) gave
an inspiring talk about the ‘Yin–Yang’ effects of ERa and
ERb. In rodent uterus 17b-oestradiol downregulates ERb
and upregulates ERa. In mammary gland of rodents, ERa
is high before puberty, low in pregnancy, high in lactation
and low after lactation. ERb on the other hand is present at
all times. ERb seems to quench the activity of ERa in both
rodent mammary and uterine tissue.
Mitchell Dowsett (Royal Marsden Hospital, London, UK)
ended the session with an interesting talk on the necessity
of intermediate markers of endocrine responsiveness.
Clinical trials usually measure response in terms of com-
plete or partial response, stable disease and progressive
disease. Dowsett suggested that we should be satisfied
with stable disease, which translates to no tumour growth
and no change in cell proliferation.
Growth factor receptors
The type I receptor tyrosine kinases and their ligands are
expressed at high levels in breast tumours, and are starting
to provide novel targets for therapy. José Baselga (Hospital
General Universitari Vall d’Hebron, Barcelona, Spain)
focused on anticancer strategies aimed at the epidermal
growth factor (EGF) receptor (ErbB1, HER1). Anti-EGF
receptor monoclonal antibody 225 directed against the
extracellular domain of EGF receptor has been found to
enhance greatly the effects of chemotherapeutic agents
that are active against breast cancer, such as taxol and
doxorubicin,  in vitro. Phase I clinical trials on a
human:murine chimeric antibody (C225) have demon-
strated its efficacy in patients with head and neck cancer,
especially in combination with cisplatin. Another target for
therapy is the tyrosine kinase activity of EGF receptor, and
a new family of potent tyrosine kinase inhibitors have
shown antitumour activity against breast cancer cell lines.
Data from phase I clinical trials of ZD1839 were presented
for the first time, ahead of a full presentation at the Ameri-3
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can Society of Clinical Oncology meeting in May. In that
trial, at least a partial response was seen in up to 20% of
patients with multiple tumour types, and in vivo inhibition of
receptor function was demonstrated, but skin and gastroin-
testinal toxicity was observed in a proportion of cases.
The Herceptin story (Genentech Inc, San Francisco, USA),
from the production of the humanized antibody through to
the early phase I clinical trials in 1990–1991, and up to
future trials that are currently seeking approval, was well
covered by Dennis Slamon (University of California, Los
Angeles, CA, USA) and Charles Vogel (University of Miami
School of Medicine, Miami, FL, USA). Of particular interest
were the controversial studies, due to start this year, on the
use of Herceptin in the adjuvant setting. From the floor, Per
Eystein Lønning (Haukeland Hospital, Bergen, Norway)
questioned the direction of such trials when the majority of
even the strongest ErbB2 overexpressors failed to respond
to Herceptin alone or in combination with traditional
chemotherapeutic agents, and wondered where the trans-
lational research to explain this was going to come from.
An interesting talk to close the session came from Klaus
Pantel (University Hospital Eppendorf, Hamburg, Germany),
who presented a strong association of micrometastatic
breast tumour cells in the bone marrow with ErbB2 posi-
tivity, opening the possibility of a more effective
immunotherapeutic target than overt metastases.
The role of TP53 and ATM in breast cancer
The ATM/TP53 pathways are fundamental in the cell’s
response to DNA damage, and dysregulation of these
pathways play a crucial part in the development of human
cancer. New insights into the mechanisms of these path-
ways are opening up exciting possibilities for selective
nongenotoxic cancer chemotherapeutic strategies.
Tak Mak (Ontario Cancer Institute, Toronto, Ontario,
Canada) focused on the recently identified checkpoint
kinase (chk)2, which directly phosphorylates p53 in
response to g-radiation-induced DNA damage. Chk2–/–
embryonic stem cells failed to maintain g-irradiation-induced
arrest in the G2 phase of the cell cycle, and Chk2–/– thymo-
cytes were resistant to DNA damage-induced apoptosis.
David Lane (University of Dundee, Dundee, UK) concen-
trated on the p53 modulator mdm2, and the potential for
anti-mdm2 monoclonal antibodies or antisense oligonu-
cleotides as nongenotoxic chemotherapeutic agents. He
also described the upstream inhibitor of mdm2, Arf, which
is a potent activator of the p53 response.
Curtis Harris (National Cancer Institute, Bethesda, MA,
USA) provided evidence for the contribution of two DNA
helicases, XPB and XPD, which are associated with xero-
derma pigmentosum, toward p53-mediated apoptosis.
Data implicating other DNA helicases associated with
Werner syndrome and Bloom syndrome in p53-mediated
apoptosis were also presented.
Other talks in this session included that by Scott Lowe
(Cold Spring Harbor Laboratory, New York, NY, USA), who
described p53 action in apoptosis and senescence, and
suggested that selection against apoptosis during tumour
development can give rise to drug-resistant tumours.
Richard Gatti (University of California, Los Angeles, CA,
USA) and Janet Hall (International Agency for Research
on Cancer, Lyon, France) discussed the increased cancer
susceptibility and radiation sensitivity of ataxia telangiecta-
sia gene (ATM) heterozygotes, and argued for two popula-
tions of ATM heterozygotes with different phenotypes.
Cell cycle and apoptosis
Although much time was devoted to the ATM/TP53 path-
ways, and their associations with cell cycle control and
apoptosis, these two topics were confined to single pre-
sentations in their own right.
Jiri Bartek (Danish Cancer Society, Copenhagen, Denmark)
examined the restriction point switch in late G1 phase of the
cell cycle, and addressed the question regarding whether
the RB–E2F pathway was the only physiological way to
commit mammalian cells to DNA replication. Evidence was
presented for a parallel myc-controlled pathway, which is
independent of and co-operates with the RB pathway.
The role of apoptosis in breast cancer was presented by
Charles Streuli (University of Manchester, Manchester,
UK), who highlighted cell adhesion as a dominant signal
for the survival of epithelial cells in the breast. The removal
of adhesion signals from cells in culture leads to apopto-
sis, and the basement membrane was shown to play a crit-
ical role in cell survival via the integrin class of receptors
and focal adhesion kinases, which signal to the Bcl-2
family of apoptosis-regulating proteins. An important point
was raised in the discussion about the breast epithelial
cells commonly used in culture without attachment to an
extracellular matrix; it was pointed out that the majority of
commercially available ‘normal mammary epithelial cells’
are not derived from the luminal epithelium, but are in fact
myoepithelial cells.
Angiogenesis and telomerase activity
Microvessel density as an independent prognostic factor
in breast cancer has highlighted the importance of angio-
genesis in the development of tumours. Adrian Harris
(Imperial Cancer Research Fund, Oxford, UK) examined
the role of hypoxia in switching on angiogenesis by the
activation of vascular endothelial growth factor. Two
hypoxia inducible transcription factors (hif1 and hif2) have
been identified as mediating two different hypoxia-regu-lated pathways. A novel target for gene therapy has been
identified downstream of hif – the carbonic anhydrase
CA9 – which appears to regulate tumour pH and may be
associated with drug resistance.
The telomerase story was eloquently covered by Jerry
Shay (University of Texas, Dallas, TX, USA). The emer-
gence of telomerase inhibitors as potential breast cancer
chemotherapeutic agents has been strengthened by
results showing the induction of apoptosis in immortalized
human breast epithelial cells by antisense therapies. In the
clinical setting, it is suggested that telomerase inhibitors
may be most beneficially used after surgery in combination
with chemotherapy/radiotherapy, and/or synergistically
with other compounds such as antiangiogenic factors.
How to implant our knowledge of the molecular
biology of breast cancer into the clinic?
Jean-Marc Nabholtz (University of Alberta, Edmonton,
Canada) opened the session with a historic overview of
chemotherapy in breast cancer, and further outlined some
of the current issues with newer combined regimens.
Jan GM Klijn (Dr Daniel den Hoed Cancer Clinic, Rotter-
dam, The Netherlands) described factors that predict
response to endocrine therapy. High ER and progres-
terone receptor levels are associated with greater
response to tamoxifen, whereas high p53 expression is
associated with poorer response to tamoxifen. HER2/neu
is a weak prognostic factor in breast cancer, but a strong
predictor for lack of response to endocrine therapy. Klijn
presented data showing that the lowest response to
tamoxifen is found in the group with p53 mutations and
lowest ER levels. He also described a breast cancer activ-
ity resistance locus (BCAR-1) on 16q; tumours with low
level of BCAR-1 have higher response rate with tamoxifen.
Per Eystein Lønning (Haukeland University Hospital,
Bergen, Norway) ended the session with an inspiring talk
on whether we are using the right approaches in clinical
trials. He suggested that we ought to limit the testing of
new cocktails, and instead use the biology of the tumour
to guide us to the proper therapy. Furthermore, he under-
lined the advantages of using sequential rather than com-
bined therapy; this should facilitate the use of predictive
factors and reduce toxicity.
This session clearly outlined how basic science can be inte-
grated into the clinic, and perhaps also, as the last speaker
mentioned, what the clinic can add to basic science.
New technologies in defining the tumour
genotype
The closing session of the meeting concentrated on some
of the new molecular techniques that look set to greatly
facilitate investigations into breast cancer biology.
The development of tissue microarrays to enable high-
throughput molecular profiling was presented by Olli
Kallioniemi (National Institutes of Health, Bethesda, MA,
USA). The production of a ‘tissue chip’ containing
500–1000 core biopsies of individual tumours allows the
examination of DNA, RNA and protein targets in a large
number of tissues in single experiments. The issue of
whether small foci of breast tumours truly reflect the
whole specimen, given breast tumour heterogeneity, was
raised, but evidence was presented that suggest that
perhaps this heterogeneity may not be as important as
was thought.
Joe Gray (University of California, San Francisco, CA,
USA) detailed molecular cytogenetic approaches to
analyze genome evolution in human breast cancers. CGH
investigates the population average of tumour cells, and
evidence was presented to indicate that the ‘average’
tumour genotype arises early and changes slowly during
cancer progression. The analysis of individual cells carried
out using fluorescent in situ hybridization paradoxically
suggest a drastic cell–cell variability in genome content,
leading to the interpretation that the production of a cell
with an advantageous genome change may be an
extremely rare event in breast tumourigenesis.
Finally David Botstein (Stanford University, Stanford, Cali-
fornia, USA) discussed genome-wide investigations using
cDNA microarrays. By utilizing clustering analysis of
expressed genes from a series of breast cancers, distinct
subtypes of tumours could be identified with important
implications for prognosis and treatment. Differences in
gene expression from the nonepithelial cells in the
tumours could also be analyzed using this approach. Fur-
thermore, investigations of breast cancer cell lines reiter-
ated the point that these cultures may be derived either
from the luminal or myoepithelial cells, with very different
patterns of gene expression. There can be little doubt that
array technology is going to open up a vast wealth of data
in the coming years, and the challenge for cancer biolo-
gists is going to be in the analysis and interpretation of
this data. George Klein (Karolinska Institute, Stockholm,
Sweden) summed this up by stating that we ‘must learn to
love complexity’.
Conclusion
This was an excellent conference, bringing together an
impressive array of internationally distinguished speakers
to provide a thorough state-of-the-art review of the basic
molecular science of breast cancer and its applications in
the clinic. The number of speakers who presented new
and unpublished data was a testament to the regard held
for the organizers and quality of the meeting in general. It
is to be hoped that the goal of promoting collaborations
will also bear fruit.
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